Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MPI | P34949 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5372315 | 0.83 | IDO1 (0.69) | IDO1ENPP2NOTUMNUDT1 | |
| SCHEMBL2659146 | 0.78 | IDO1 (0.64) | IDO1ENPP2GAAKDM4EALDH1A1 | |
| SCHEMBL1985682 | 0.78 | IDO1 (0.64) | IDO1ENPP2GAAALDH1A1MRGPRX4 | |
| SCHEMBL3080603 | 0.78 | ENPP2 (1.00) | IDO1ENPP2KDM4EALDH1A1 | |
| SCHEMBL16168686 | 0.78 | IDO1 (0.64) | IDO1ENPP2NOTUM | |
| SCHEMBL970723 | 0.76 | IDO1 (0.61) | IDO1ENPP2GAAKDM4ESCN2A | |
| SCHEMBL2721372 | 0.76 | IDO1 (0.60) | IDO1ENPP2GAAKDM4EALDH1A1 | |
| SCHEMBL29516758 | 0.74 | IDO1 (0.58) | IDO1ENPP2GAAKDM4EALDH1A1 | |
| SCHEMBL10066580 | 0.74 | IDO1 (0.58) | IDO1ENPP2NOTUMMRGPRX4 | |
| SCHEMBL10022419 | 0.74 | IDO1 (0.58) | IDO1ENPP2GAAMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550757-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2542089-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2017-01-18 | — | — | EP | disclosed |
| CN-103002742-B | Nuclear translocation regulator and application thereof | 卡尔约药物治疗公司 | 2016-07-13 | — | — | CN | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| CN-103002742-A | Nuclear transport modulatiors and uses thereof | KARYOPHARM THERAPEUTICS INC | 2013-03-27 | — | — | CN | disclosed |
| EP-2542089-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011109799-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | IDO1 2852/4885ENPP2 2106/4885NOTUM 4789/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | IDO1 2852/4885ENPP2 2106/4885NOTUM 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.